By Our Correspondent
National News – Nigeria has taken a major step in its fight against HIV/AIDS with the arrival of the long-acting HIV prevention injection, Lenacapavir.
The Federal Government confirmed that the medication has been delivered to the country and will soon be introduced into the national HIV prevention programme as part of broader efforts to reduce new infections and strengthen healthcare outcomes.
According to the National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP) at the Federal Ministry of Health and Social Welfare, Dr. Adebobola Bashorun, the introduction of Lenacapavir highlights Nigeria’s commitment to innovative and evidence-based health solutions.
The government, alongside healthcare partners and stakeholders, will oversee the safe rollout and integration of the injection into the country’s HIV prevention strategy.
Lenacapavir is a long-acting injectable drug used for HIV pre-exposure prophylaxis (PrEP).
Unlike daily oral preventive medications, the injection is administered only twice a year, offering a convenient alternative for individuals who may struggle to maintain daily medication routines.
Health officials believe the availability of this long-acting HIV prevention injection could significantly improve adherence to HIV prevention methods, especially among high-risk populations.
Experts say expanding prevention options will help increase access to services, reduce new HIV infections, and strengthen the country’s public health response.
The Federal Government stated that Lenacapavir will complement existing HIV testing, treatment, and prevention services already available across Nigeria.
By integrating the medication into current programmes, health authorities aim to widen prevention choices while ensuring equitable access to healthcare.
Nigeria is among 120 low- and middle-income countries expected to benefit from the medication following voluntary licensing agreements that allow generic manufacturers to produce the drug at an affordable cost.
The injection is projected to cost about $40 per person annually, making it accessible to millions who need HIV prevention services.
The introduction of Lenacapavir was approved by the Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, with support from international health partners including the Global Fund.
Officials say the development represents a major milestone in Nigeria’s efforts to end HIV as a public health threat.
With the arrival of this long-acting HIV prevention injection, Nigeria moves closer to achieving stronger epidemic control and improving the health and well-being of communities nationwide.
